

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 3458	SERIAL NO. 09/434,870
	APPLICANT: Huse et al. <i>ATTACHED TO #5</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 4, 1999	GROUP: 10F4 1643

U.S. PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>LH</i>	5,223,409	6/29/93	Ladner et al.	435	69.7	3/1/91
<i>[Vertical line]</i>	5,225,539	7/6/93	Winter	530	387.3	10/25/91
	5,264,563	11/23/93	Huse	530	25.3	12/14/92
	5,585,089	12/17/96	Queen et al.	424	133.1	6/7/95
	5,693,762	12/2/97	Queen et al.	530	387.3	6/7/95
	5,723,323	3/3/98	Kauffman et al.	435	172.3	12/2/94
	5,814,476	9/29/98	Kauffman et al.	435	69.1	6/5/95
	5,817,483	10/6/98	Kauffman et al.	435	69.1	6/5/95
	5,824,514	10/20/98	Kauffman et al.	435	91.1	6/5/95
<i>LH</i>	5,976,862	11/2/99	Kauffman et al.	435	252.3	6/5/95

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
<i>LH</i>	0 451 216B1	10/16/91	European	G12P21	00	
<i>[Vertical line]</i>	0 682 040B1	11/15/95	European	C07K16	46	
<i>[Vertical line]</i>	0 939 127 A2	09/01/99	European	G12N15	13	
<i>LH</i>						

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>12/12/00</i>
-----------------------------	---------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 3458	SERIAL NO. 09/434,870
	APPLICANT: Huse et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 4, 1999	GROUP: 1643 2 of 4

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

211		Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," <u>J. Mol. Biol.</u> 196:901-917 (1987).
1		Chothia et al., "Conformations of immunoglobulin hypervariable regions," <u>Nature</u> 342:877-883 (1989)
		Foote and Winter, "Antibody framework residues affecting the conformation of the hypervariable loops," <u>J. Mol. Biol.</u> 224:487-499 (1992).
		Glaser et al., " Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," <u>J. Immunology</u> 149:3903-3913 (1992).
		Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> 321:522-525 (1986).
		Kabat et al., "Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites," <u>J. Biol. Chem.</u> 252:6609-6616 (1977).
		Kabat et al., "Sequences of proteins of immunological interest," (5 th Ed) Washington DC: United States Department of Health and Human Services (1991). <i>INTRODUCTION & REFERENCES TO INTRODUCTION</i>
114		Kristensson et al., "Humanization of a murine antibody against <i>cryptococcus neoformans</i> polysaccharide using a novel approach," <u>Vaccines</u> 95, 39-43 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1995).

EXAMINER 	DATE CONSIDERED 12/14/00
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 3458	SERIAL NO. 09/434,870
	APPLICANT: Huse et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 4, 1999	GROUP: 1.643 RECEIVED 3 of 4 JUN 17 2000 TECH CENTER

1/1		MacCallum et al., "Antibody-antigen interactions: contact analysis and binding site topography," <u>J. Mol. Biol.</u> 262:732-745 (1996).
		Padlan, E.A., "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," <u>Mol. Immunol.</u> 28:489-498 (1991).
		Padlan, E.A., "Anatomy of the antibody molecule," <u>Mol. Immunol.</u> 31:169-217 (1994).
		Rader et al., "A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <u>Proc. Natl. Acad. Sci. USA</u> 95:8910-8915 (1998).
		Riechmann et al., "Reshaping human antibodies for therapy," <u>Nature</u> 332:323-327 (1988).
		Rosok et al., "A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab," <u>J. Biol. Chem.</u> 271:22611-22618 (1996).
		Schier et al., "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <u>J. Mol. Biol.</u> 263:551-567 (1996).
		Schreiber and Fersht, "Energetics of protein-protein interactions: Analysis of the barnase-barstar interface by single mutations and double mutant cycles," <u>J. Mol. Biol.</u> 248:478-486 (1995).
		Singer et al., "Optimal humanization of 1B4, an anti-CD 18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences," <u>J. Immunol.</u> 150:2844-2857 (1993).
1/1		Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Eng.</u> 7:805-814 (1994).


EXAMINER 	DATE CONSIDERED 12/12/00
--------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 3458	SERIAL NO. 09/434,870
	APPLICANT: Huse et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 4, 1999	GROUP: 4 of 4 1643

LTP		Thompson et al., "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity," <u>J. Mol. Biol.</u> 256:77-88 (1996).
		Watkins et al., "Determination of the relative affinities of antibody fragments expressed in <i>Escherichia coli</i> by enzyme-linked immunosorbent assay," <u>Anal. Biochem.</u> 253:37-45 (1997).
		Watkins et al., "Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries," <u>Anal. Biochem.</u> 256:169-177 (1998).
↓		Wu et al., "Stepwise <i>in vitro</i> affinity maturation of Vitaxin, and $\alpha_v\beta_3$ -specific humanized mAb," <u>Proc. Natl. Acad. Sci. USA</u> 95:6037-6042 (1998).
LM		Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <u>J. Immunol.</u> 155:1994-2004 (1995).

EXAMINER 	DATE CONSIDERED 12/12/00
--	--------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.